$20.17
0.432.18%
Dern. MÀJ: Oct 27, 4:41 PM
Acadia Pharmaceuticals (ACAD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
fiscal year (2026) a publié ses dernières prévisions le $1.24B - $1.3B pour Acadia Pharmaceuticals {{epsDirection}}. La société a prévu un chiffre d'affaires compris entre {{epsPriorRange}} et {{revenueDirection}} pour la période.
Par rapport aux prévisions précédentes, {{newestDate}} {{directionSummary}} ses prévisions de chiffre d'affaires ont été revues à la baisse, passant d'une fourchette précédente de undefined à undefined.
undefined a publié undefined mises à jour de ses recommandations entre undefined et undefined. undefined
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.04 | $0.07 | $0.13 | $0.14 |
| Actual | $0.18 | $0.02 | $0.14 | $0.26 |
| Surprise | +350.0% | -71.4% | +7.69% | +85.7% |
| Revenue | ||||
| Estimate | $295.2M | $280.6M | $292.5M | $275.4M |
| Actual | $308.0M | $268.1M | $284.0M | $278.6M |
| Surprise | +4.31% | -4.48% | -2.92% | +1.19% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.19 | $0.22 | $0.18 | $0.20 |
| Revenue | ||||
| Consensus | $333.0M | $362.1M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $0.18 | $0.04 | 350.0 % |
| Q1 | May 6, 2026 | $0.02 | $0.07 | -71.4 % |
| Q4 | Feb 25, 2026 | $0.14 | $0.13 | 7.69 % |
| Q3 | Nov 5, 2025 | $0.26 | $0.14 | 85.7 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $307.96M | $295.22M | 4.31 % |
| Q1 | May 6, 2026 | $268.06M | $280.65M | -4.48 % |
| Q4 | Feb 25, 2026 | $283.99M | $292.52M | -2.92 % |
| Q3 | Nov 5, 2025 | $278.63M | $275.36M | 1.19 % |